Israel state records י"ב באדר התשס"ו March 12, 2006
Download 0.86 Mb.
|
- Navigate this page:
- 137437 [21][11] 1 – פניל – 4 – אמינו – 6, 7
- [6, 7, 1 – ih] אינדולים פוספודיאסטראז
- 137804 [21][11] תערובות להבקרת אלמנטים אופטיים
- 137909 [21][11] שיטה לגילוי של חומצות גרעין מסוימותתוך שימוש ב– PCR
- 137943 [21][11] כסא גלגלים
- 138048 [21][11] שימוש במעכבי אספרגיניל אנדופפטידז לטיפול במחלה חיסונית
- 138110 [21][11] השימוש בנגזרי חומצה פומרית להכנת תרופות לרפואת השתלות
- 138183 [21][11] פורמולציה להורדת pH ומערכת הובלה עבור טמפון
- 138185 [21][11] תמיסה אותומלית המכילה גליקוגן
- 138249 [21][11] ניפוי דיפרנציאלי איכותי
|
[57] A compound of the formula 
wherein Rx is cyano or bromo; R1 is halo; R2 is C1-C8 alkyl, and pharmaceutically acceptable salts, and the prodrug of the formula 
wherein Rx, R1 and R2 are as defined above, R3 is H, (CHm)nNR5R6; R4 is H, C1-C3 alkyl, (CHm)nNR5R6, (CHm)nC(=O)R5, (CHm)nOH, OR7, halo, CF3 or CN; or R5 is H, C1-C3 alkyl, C(=O)R7 or a peptide of 1 to 4 amino acids; R6 is H, C1-C3 alkyl; R7 is H, C1-C12 alkyl, (CHm)nNR5R6; X and its encompassing circle define a ring selected from cyclohexanoyl, cyclohexenyl, phenyl, morpholino, pyridyl, pentenyl, naphthyl, quinolyl, tetrahydroisoquinolyl, indolyl, benzimidazolyl, benzopyridyl; m is independently 1 or 2; n is independently 0, 1 or 2; p is 0 or 1; and pharmaceutically acceptable salts thereof. __________
[57] Aminodiazepinoindoles of the formula 
in which B is OH or NH2. __________
[57] An optical polishing formulation comprised of an aqueous slurry containing from 5 to 20% by weight of solids in which from 85-95% of the solids content is provided by an alpha alumina component with a mean particle size less than 0.5 μm, and correspondingly 15 to 5% by weight of the solids content is provided by ceria in the form of a powder with a mean particle size from 0.2 to 4 μm, formulations comprising an ozidizing agent being excluded. __________
[57] A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising (a) subjecting said sample to an amplification reaction using a set of nucleotides, at least one of which is fluorescently labeled, (b) contacting amplification product with a probe under conditions in which the probe will hybridise to said target sequence, said probe comprising a reactive molecule which is able to absorb fluorescence from or donate fluorescent energy to said fluorescent labeled nucleotide and (c) monitoring fluorescence of said sample. __________
[57] A standard wheel chair (1) which comprises at least one construction (hereinafter called "baller"), said baller (2) consisting of at least one rod (3) being connected to the wheel chair and carrying a frame (8) connected to said rod by connecting means (10); a ball (9) being located within said frame. 
__________
[57] A method of reducing the processing of a protein antigen by a MHC Class II molecule by a cell, the method comprising contacting the cell with an inhibitor of asparaginyl endopeptidase, wherein said method is not carried out in vivo in humans. An inhibitor of asparaginyl endopeptidase which has the structure Bl-(Xa-Xn)-Asn-Q wherein B1 is any suitable N terminal blocking group; Xa-Xn are the n amino acid residues immediately N terminal to an Asn cleavage site in the invariant chain of Class II MHC molecules; Asn is an asparagine residue; and Q is a group capable of reacting with the active site of asparaginyl endopeptidase, and the structure (Xb-Xc)Asn(Xd-Xe) wherein (Xb-Xc) are the r amino acid residues immediately N terminal to an Asn cleavage site in the invariant chain of Class II MHC molecules and (Xd-Xe) are the s amino acid residues immediately C terminal to an Asn cleavage site in the said invariant chain; Asn is an asparagine residue; and r and s are independently between 2 and 25, provided that the inhibitor is not the peptide CVFPNGTEVPNTRSRGHHN or the peptide ATKYGNMTEDHVMHLLQNA are also claimed as novel. __________
[57] The use of one or more fumaric acid –C1-C5-monoalkylester(s) in the form of a salt with mono- or bivalent cations or in the form of free acid, either alone or in combination with a di-C1-C5-alkylfumarate for manufacture of a medicament for treating host-versus-graft reactions in organ and cell transplantation. __________
[57] A formulation effective in reducing the pH in a menstruating vagina or in a tampon inserted therein to below pH 5.5 comprising:(a) 3-80% by weight of a solid organic acid polymer; (b) 92-15% by weight of a solid organic acid; and (c) 5-30% of a wetting agent. __________
[57] Use of a glycogen polysaccharide, as an active ingredient, substantially free of nitrogen, when determined by the Kjeldahl method, for the manufacture of an ophthalmic sterile aqueous solution useful as an artificial tear. __________
Directory: Units -> RashamHaptentim -> Units -> patent -> yoman Units -> Perform and explain geodetic computations Units -> Demonstrate and apply advanced knowledge of programming techniques for electrotechnology Units -> Nzqa registered unit standard 22561 version 3 Units -> Nzqa registered unit standard 22528 version 2 Units -> Nzqa registered unit standard 26968 version 1 Units -> Nzqa registered unit standard 10212 version 5 Download 0.86 Mb. Share with your friends:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||